Frontlight ResearchEarly access
Active, not recruitingNo phase
Transcatheter Mitral Valve Replacement System (TMVR) Pilot Study and The Early Feasibility Study of the TMVR Transseptal System
Key facts
- Who runs it
- Medtronic Cardiovascular
- Where
- Ann Arbor, Atlanta, Charlottesville, Chicago, Dallas, Grand Rapids, Houston, Los Angeles, Milwaukee, Minneapolis, New York, Phoenix, Portland, St Louis, and Wormleysburg, United StatesSee the 21 sitesAlso in 6 other countries, 11 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 128 people enrolled
- Started
- Apr 2015
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- Twelve TMVR Implant
- Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System
- Record updated
- 14 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Severe mitral regurgitation (PILOT)
- moderate-severe or severe mitral regurgitation (EFS)
- Symptomatic mitral regurgitation (NYHA Class II-IV)
- Deemed to be at high risk for conventional mitral valve surgery by the local heart team (including, at minimum, a cardiac surgeon, interventional cardiologist, and an echocardiologist) (PILOT and EFS)
- Subjects anatomically suitable for the Intrepid TMVR delivery system, including transfemoral and transseptal access (EFS only)
- Native mitral valve geometry and size compatible with the Intrepid™ TMVR (PILOT)
Who cannot take part
- Prior valve surgery or need for other valve surgery
- Prior stroke within 30 days (PILOT) or 90 days (EFS)
- Prior myocardial infarction 90 days (EFS)
- Gastrointestinal bleeding within 6 months (PILOT)
- History of, or active, endocarditis if antibiotics are required (EFS)
- Left ventricular ejection fraction (LVEF) < 20 (PILOT) or <30% (EFS)
- Renal insufficiency; Serum Creatinine > 2.5 mg/dL (PILOT) or Creatinine Clearance <30 cc/min (EFS)
- Evidence of intracardiac mass, thrombus, or vegetation
- Need for coronary revascularization
Where in United States
Also in 6 other countries, 11 sites
- University of Michigan Health System - University Hospital - PILOTAnn Arbor, United States
- Piedmont Atlanta Hospital - PILOTAtlanta, United States
- University of Virginia Medical Center - EFSCharlottesville, United States
- Northwestern Memorial Hospital - PILOTChicago, United States
- Baylor Jack and Jane Hamilton Heart and Vascular Hospital - PILOTDallas, United States
- Corewell Health - EFSGrand Rapids, United States
- Houston Methodist Hospital - PILOTHouston, United States
- Cedars-Sinai Medical Center - PILOTLos Angeles, United States
- Aurora Saint Luke's Medical Center - EFSMilwaukee, United States
- Aurora Saint Lukes Medical Center - PILOTMilwaukee, United States
- Abbott Northwestern Hospital - EFSMinneapolis, United States
- Abbott Northwestern Hospital - PILOTMinneapolis, United States
- New York-Presbyterian Hospital Columbia University Medical Center - EFSNew York, United States
- New York-Presbyterian Hospital Columbia University Medical Center - PILOTNew York, United States
- NYU Langone Medical Center - PILOTNew York, United States
- The Mount Sinai Hospital (New York NY) - EFSNew York, United States
- The Mount Sinai Hospital (New York NY) - PILOTNew York, United States
- Abrazo Arizona Heart Hospital - EFSPhoenix, United States
- Oregon Health & Science University Hospital - EFSPortland, United States
- Barnes Jewish Hospital - PILOTSt Louis, United States
- UPMC Pinnacle Harrisburg Campus - EFSWormleysburg, United States
About the trial
What the trial wants to find out
PILOT:
Read full original descriptionShow less
The study is a pilot trial to evaluate the safety and performance of the Twelve TMVR System in high risk mitral regurgitation patients.
EFS:
The study is an Early Feasibility Study to evaluate the safety and performance of the Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System with Transfemoral Transseptal access in Patients with moderate-Severe or severe, Symptomatic Mitral Regurgitation
The group in the trial
- Transcatheter Mitral Valve Replacement (TMVR) ImplantTreatment being tested
Twelve TMVR Implant
Treatment: Twelve TMVR Implant and Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Initial Evaluation of the Safety and Performance of the Transcatheter Mitral Intrepid Valve Replacement System in Patients With Severe, Symptomatic Mitral Regurgitation
- Publications
- Five-year outcomes of the early-generation Intrepid transapical transcatheter mitral valve replacement system.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2026
- 30-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results.JACC. Cardiovascular interventions, 2022
- Early Experience With New Transcatheter Mitral Valve Replacement.Journal of the American College of Cardiology, 2018
- Record updated
- 14 January 2026